PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29153032-2	2017	Inhibition of HIF-PH by roxadustat leads to a rapid increase in cytoplasmic HIF-alpha concentrations, followed by translocation of HIF-alpha to the nucleus and upregulation of HIF-responsive genes, including erythropoietin.	roxadustat	24-34	erythropoietin	Rattus norvegicus	208-222	
35164384-0	2022	Effects of Roxadustat on Erythropoietin Production in the Rat Body.	roxadustat	11-21	erythropoietin	Rattus norvegicus	25-39	
35164384-6	2022	Using this method, we examined the effects of the PHD inhibitor, Roxadustat (ROX), and severe hypoxia on Epo production in various tissues in rats.	roxadustat	65-75	erythropoietin	Rattus norvegicus	105-108	
35164384-6	2022	Using this method, we examined the effects of the PHD inhibitor, Roxadustat (ROX), and severe hypoxia on Epo production in various tissues in rats.	roxadustat	77-80	erythropoietin	Rattus norvegicus	105-108	
32487538-4	2020	We hypothesized that roxadustat, an orally available small-molecule inhibitor of HIF-PH, would increase EPO production and promote erythropoiesis in animal models of anemia.	roxadustat	21-31	erythropoietin	Rattus norvegicus	104-107	
32487538-5	2020	In cells, roxadustat increased both HIF-1alpha and HIF-2alpha proteins, leading to an increase in EPO production, even in the presence of EPO-suppressing inflammatory cytokines.	roxadustat	10-20	erythropoietin	Rattus norvegicus	98-101	
32487538-9	2020	In conclusion, by activating the HIF pathway, roxadustat increased EPO production, elevated Hb, corrected anemia, and improved iron homeostasis.	roxadustat	46-56	erythropoietin	Rattus norvegicus	67-70	
32487538-10	2020	The coordinated erythropoietic response stimulated by roxadustat, involving both EPO production and mobilization of iron stores, makes this compound a promising treatment of anemia of CKD and anemia associated with functional iron deficiency.	roxadustat	54-64	erythropoietin	Rattus norvegicus	81-84	
32487538-11	2020	SIGNIFICANCE STATEMENT: Roxadustat is a novel orally available small-molecule inhibitor of HIF prolyl hydroxylase enzymes that reversibly stabilizes HIF-alpha, thus activating transcription of HIF-dependent genes, including EPO and regulators of iron homeostasis.	roxadustat	24-34	erythropoietin	Rattus norvegicus	224-227	
32487538-13	2020	The coordinated erythropoietic response that increases EPO production and mobilizes iron stores makes roxadustat a promising treatment for anemia of chronic kidney disease and anemia associated with functional iron deficiency.	roxadustat	102-112	erythropoietin	Rattus norvegicus	55-58